REVOLUTION MEDICINES INC

Revolution Medicines’ Bloomberg 500 debut and FDA approval of Rasonque show a 48% survival lift in metastatic pancreatic cancer, boosting investor confidence and clinical adoption.

Revolution Medicines reports Q2 2026 earnings, nearly $4 B cash, and FDA NDA for daraxonrasib—offering a new RAS‑inhibitor option in metastatic pancreatic cancer.

Paradigm Biocapital’s stake boost in Jade Biosciences signals strong confidence in its precision oncology pipeline and partnership network, offering investors a rare glimpse into biopharma’s next‑generation therapeutic opportunities.

Revolution Medicines CEO sells option‑acquired shares amid a brokerage price‑target upgrade—insider liquidity, strong revenue growth, and strategic reimbursement plans reveal a biotech firm poised for long‑term growth.

Revolution Medicines CFO’s recent insider trades show routine portfolio moves, with a net 4% gain—no strategic shift, just standard 10(b)(5)(1) activity.

Revolution Medicines CFO’s June 24 trades reveal insider confidence and regulatory strategy, offering investors insight into the company’s governance and future outlook.

Revolution Medicines files a routine insider sale under Rule 144, but its oncology pipeline and FDA plans for RMX‑101 remain on track, offering a new lung‑cancer option.

Revolution Medicines’ 10‑b5‑1 sales show prudent tax‑liquidity handling while maintaining a strong pipeline, positive cash flow and a cost‑effective tech strategy that boosts payer appeal and patient access in oncology.

Revolution Medicines COO Margaret Horn’s insider trades reveal how executive equity activity under a 10(b)(5) plan can boost investor confidence and align management with shareholder interests.

Revolution Medicines’ Rule 144 filings show routine RSU sales and a $14 m officer sale that’s under 0.5% of shares—minimal impact on value or strategy.